HUTCHMED (China) Limited secured conditional approval from the China National Medical Products Administration (NMPA) for its novel oral inhibitor fanregratinib, branded as ATLED. The drug is approved for treating adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements who have received prior systemic therapy.

The regulatory milestone follows data from the pivotal Phase II/IIIb clinical trial (NCT04353375). Results presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2026 demonstrated strong clinical activity in this aggressive malignancy subtype.

Clinical Performance Data

The study met its primary endpoint with an Independent Review Committee-assessed objective response rate (ORR) of 42.5% (95% CI: 30.0%–53.6%). Secondary endpoints highlighted rapid onset and durable control:

Median time to response was 1.4 months, while median duration of response stood at 6.9 months (95% CI: 5.6–8.5). These figures underscore the drug’s efficacy in pretreated advanced ICC patients.

What the Numbers Show

The divergence between the high disease control rate (83.9%) and the moderate objective response rate (42.5%) suggests significant tumor stabilization even among non-responders. This pattern is critical in ICC, where the five-year overall survival rate is approximately 9%, indicating that ATLED offers a meaningful extension of life beyond historical standards.

Commercial Outlook

Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, stated the company is prepared to leverage its established commercial infrastructure to bring ATLED to patients rapidly. The approval addresses a critical therapeutic gap, as ICC accounts for 8.2-15.0% of primary liver cancers globally.

Enrollment for the confirmatory Phase IIIb cohort began in January 2026 to further validate clinical benefits and safety. HUTCHMED retains all worldwide rights to fanregratinib, positioning the asset for potential global expansion beyond China.

Hutchmed (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) announced on August 17, 2026 that its Phase III SAFFRON trial met its primary and key secondary endpoints. The study showed that the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) delivered statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to doublet platinum-based chemotherapy.

This marks the first global Phase III trial to demonstrate significant progression-free and overall survival benefits in this setting. The results reinforce TAGRISSO as the backbone therapy across EGFR-mutated lung cancer.

The trial focused on patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who had tumors with high levels of MET overexpression or amplification after progressing on prior TAGRISSO treatment. This patient population faces poor prognosis due to MET-driven resistance, a common mechanism of resistance to third-generation EGFR-tyrosine kinase inhibitors (TKIs).

Trial Design and Scope

SAFFRON was a randomized, open-label, multi-center global Phase III trial involving 338 patients across 230 centers in 29 countries. The regions included North America, Europe, South America, and Asia. Patients received ORPATHYS at 300mg twice daily added to TAGRISSO at 80mg once daily.

Patient selection was prospective, using high MET level cut-offs identified in the earlier SAVANNAH Phase II trial. Biomarker testing utilized immunohistochemistry (IHC) for protein detection and fluorescence in situ hybridization (FISH) for DNA sequence detection.

Clinical Significance

Professor Shun Lu, Director of Shanghai Lung Cancer Center and principal investigator, noted the results represent a critical advance for patients with no available biomarker-directed oral treatment options in this setting. He emphasized the urgency of MET testing to inform treatment decisions given that MET is one of the most common drivers of progression on targeted therapy.

Dr Weiguo Su, CEO and Chief Scientific Officer of Hutchmed, stated the data reinforce robust efficacy previously demonstrated in the SACHI Phase III trial, which supported approval in China. The results provide clear evidence to support global registrations of the combination therapy.

Dr Susan Galbraith, Executive Vice President of Oncology Hematology R&D at AstraZeneca, highlighted the benefit of adding ORPATHYS to backbone therapy TAGRISSO to address MET overexpression while maintaining EGFR suppression. She described the combination as aiming to deliver the first biomarker-directed, all-oral option in this setting globally.

Safety and Regulatory Outlook

The safety profile for the combination was consistent with the known profiles of each medicine individually, with no new safety findings reported. The data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.

ORPATHYS plus TAGRISSO is already approved in China for locally advanced or metastatic EGFRm NSCLC with MET amplification after disease progression on EGFR-TKI therapy based on the SACHI trial. The combination was also granted temporary authorization in Switzerland based on results from the SAVANNAH Phase II trial.

What the Numbers Show

The source indicates that approximately one in three patients with EGFRm NSCLC develop MET overexpression or amplification after progressing on third-generation EGFR-TKIs. Specifically, an estimated 34% of tumors develop high levels of MET overexpression or amplification in this setting. This prevalence figure underscores the significant unmet need addressed by the SAFFRON trial results, positioning the combination therapy for a substantial segment of the resistant NSCLC population.